Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 03 2020
revised: 01 04 2020
accepted: 04 04 2020
pubmed: 25 5 2020
medline: 24 8 2021
entrez: 25 5 2020
Statut: ppublish

Résumé

Seizures are an under-reported feature of the SATB2-associated syndrome phenotype. We describe the electroencephalographic findings and seizure semiology and treatment in a population of individuals with SATB2-associated syndrome. We performed a retrospective review of 101 individuals with SATB2-associated syndrome who were reported to have had a previous electroencephalographic study to identify those who had at least one reported abnormal result. For completeness, a supplemental survey was distributed to the caregivers and input from the treating neurologist was obtained whenever possible. Forty-one subjects were identified as having at least one prior abnormal electroencephalography. Thirty-eight individuals (93%) had epileptiform discharges, 28 (74%) with central localization. Sleep stages were included as part of the electroencephalographies performed in 31 individuals (76%), and epileptiform activity was recorded during sleep in all instances (100%). Definite clinical seizures were diagnosed in 17 individuals (42%) with a mean age of onset of 3.2 years (four months to six years), and focal seizures were the most common type of seizure observed (42%). Six subjects with definite clinical seizures needed polytherapy (35%). Delayed myelination and/or abnormal white matter hyperintensities were seen on neuroimaging in 19 individuals (61%). Epileptiform abnormalities are commonly seen in individuals with SATB2-associated syndrome. A baseline electroencephalography that preferably includes sleep stages is recommended during the initial evaluation of all individuals with SATB2-associated syndrome, regardless of clinical suspicion of epilepsy.

Sections du résumé

BACKGROUND
Seizures are an under-reported feature of the SATB2-associated syndrome phenotype. We describe the electroencephalographic findings and seizure semiology and treatment in a population of individuals with SATB2-associated syndrome.
METHODS
We performed a retrospective review of 101 individuals with SATB2-associated syndrome who were reported to have had a previous electroencephalographic study to identify those who had at least one reported abnormal result. For completeness, a supplemental survey was distributed to the caregivers and input from the treating neurologist was obtained whenever possible.
RESULTS
Forty-one subjects were identified as having at least one prior abnormal electroencephalography. Thirty-eight individuals (93%) had epileptiform discharges, 28 (74%) with central localization. Sleep stages were included as part of the electroencephalographies performed in 31 individuals (76%), and epileptiform activity was recorded during sleep in all instances (100%). Definite clinical seizures were diagnosed in 17 individuals (42%) with a mean age of onset of 3.2 years (four months to six years), and focal seizures were the most common type of seizure observed (42%). Six subjects with definite clinical seizures needed polytherapy (35%). Delayed myelination and/or abnormal white matter hyperintensities were seen on neuroimaging in 19 individuals (61%).
CONCLUSIONS
Epileptiform abnormalities are commonly seen in individuals with SATB2-associated syndrome. A baseline electroencephalography that preferably includes sleep stages is recommended during the initial evaluation of all individuals with SATB2-associated syndrome, regardless of clinical suspicion of epilepsy.

Identifiants

pubmed: 32446642
pii: S0887-8994(20)30122-3
doi: 10.1016/j.pediatrneurol.2020.04.006
pii:
doi:

Substances chimiques

Matrix Attachment Region Binding Proteins 0
SATB2 protein, human 0
Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-100

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Hannah Lewis (H)

University of Arkansas for Medical Sciences School of Medicine, Little Rock, Arkansas.

Debopam Samanta (D)

Section of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Jenny-Li Örsell (JL)

Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Katherine A Bosanko (KA)

Section of Genetics and Metabolism, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Amy Rowell (A)

Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Melissa Jones (M)

Houston Area Pediatric Neurology, Houston, Texas.

Russell C Dale (RC)

Kids Neuroscience Centre, Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, Australia.

Sasidharan Taravath (S)

Department of Pediatric Neurology, Coastal Childrens service, Wilmington, North Carolina.

Cecil D Hahn (CD)

Division of Neurology, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Canada.

Deepa Krishnakumar (D)

Department of Paediatric Neurology, Addenbrooke's Hospital, Cambridge, UK.

Sarah Chagnon (S)

Division of Child and Adolescent Neurology, Children's Hospital of the Kings Daughters, Norfolk, Virginia.

Stephanie Keller (S)

Division of Pediatric Neurology, Department of Pediatrics, Emory University, Atlanta, Georgia.

Eveline Hagebeuk (E)

Stichting Epilepsie Instellingen Nederland (SEIN) Zwolle, the Netherlands.

Sheel Pathak (S)

Division of Pediatric and Developmental Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri.

E Martina Bebin (EM)

Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama.

Daniel H Arndt (DH)

Division of Pediatric Neurology, Department of Pediatrics, Beaumont Children's, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.

John J Alexander (JJ)

Division of Neurology, Seattle Children's Hospital, Seattle, Washington.

Gayatra Mainali (G)

Division of Pediatric Neurology, Penn State College of Medicine, Hershey, Pennsylvania.

Giangennaro Coppola (G)

Department of Medicine, Surgery and Dentistry, Child and Adolescent Neuropsychiatry, University of Salerno, Italy.

Jane Maclean (J)

Pediatric Neurology, Palo Alto medical foundation, San Jose, California.

Steven Sparagana (S)

Department of Neurology, Texas Scottish Rite Hospital for Children and University of Texas Southwestern Medical Center, Dallas, Texas.

Nancy McNamara (N)

Division of Child Neurology, Department of Pediatrics, Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan.

Douglas M Smith (DM)

Minnesota Epilepsy Group, Saint Paul, Minnesota.

Víctor Raggio (V)

Departamento de Genética, Facultad de Medicina, Udelar, Uruguay.

Marcos Cruz (M)

HighPoint Neurology Associates, Hendersonville, Tennessee.

Alberto Fernández-Jaén (A)

Department of Pediatric Neurology, Hospital Universitario Quirónsalud and Universidad Europea de Madrid, Madrid, Spain.

Maina P Kava (MP)

Department of Neurology, Perth Children's Hospital, Western Australia, Australia; School of Paediatrics and Child Health, University of Western Australia, Australia.

Lisa Emrick (L)

Department of Pediatrics, Section of Neurology and Developmental Neuroscience, and Department of Molecular and Human Genetics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas.

Jennifer L Fish (JL)

Department of Biological Sciences, University of Massachusetts Lowell, Lowell, Massachusetts.

Adeline Vanderver (A)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Guy Helman (G)

Murdoch Children's Research Institute, The Royal Children's Hospital, Victoria, Australia; Institute for Molecular Bioscience, The University of Queensland, Queensland, Australia.

Tyler M Pierson (TM)

Departments of Pediatrics and Neurology & The Board of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, California.

Yuri A Zarate (YA)

Section of Genetics and Metabolism, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: yazarate@uams.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH